Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Yuan, Shuanghu T ^a,b   Brown, Richard K J ^a   Zhao, Lujun ^a,c   Ten Haken, Randall K ^a   Gross, Milton ^a   Cease, Kemp B ^a   Schipper, Matt ^a   Stanton, Paul ^a   Yu, Jinming ^b   Kong, Feng Ming S ^a,d,e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

FDG PET; Non small cell lung cancer; Radiation esophagitis; Standard uptake value (SUV)

Indexed keywords

FLUORODEOXYGLUCOSE; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; AORTA ARCH; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; ESOPHAGITIS; ESOPHAGUS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIMARY TUMOR; PROSPECTIVE STUDY; RADIATION DOSE; AREA UNDER THE CURVE; CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECTS; FOLLOW UP; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIATION INJURIES; RADIATION RESPONSE; SCINTISCANNING; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; ESOPHAGITIS; ESOPHAGUS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIATION INJURIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84899134675     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-37     Document Type: Article

References (19)

1. Mascarenhas F, et al. Acute secondary effects in the esophagus in patients undergoing radiotherapy for carcinoma of the lung. Am J Clin Oncol 1989, 12:34-40. 10.1097/00000421-198902000-00008, 2536215.
2. Werner-Wasik M, et al. Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (rtog) database. Clin Lung Cancer 2011, 12:245-251. 10.1016/j.cllc.2011.03.026, 21726824.
3. Cox JD, et al. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 radiation therapy oncology group (rtog) trials. Int J Radiat Oncol Biol Phys 1993, 27:493-498. 10.1016/0360-3016(93)90371-2, 8226140.
4. Challand T, et al. Esophageal toxicity of radiation therapy: clinical risk factors and management. Cancer Radiother 2012, 16:364-371. 10.1016/j.canrad.2012.07.180, 22925486.
5. Maguire PD, et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys 1999, 45:97-103. 10.1016/S0360-3016(99)00163-7, 10477012.
6. Takeda K, et al. Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2005, 62:626-629. 10.1016/j.ijrobp.2005.04.004, 15936536.
7. Ozgen A, Hayran M, Kahraman F. Mean esophageal radiation dose is predictive of the grade of acute esophagitis in lung cancer patients treated with concurrent radiotherapy and chemotherapy. J Radiat Res 2012, 21:21.
8. Singh AK, Lockett MA, Bradley JD. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2003, 55:337-341. 10.1016/S0360-3016(02)03937-8, 12527046.
9. Bakheet SM, Powe J. Benign causes of 18-fdg uptake on whole body imaging. Semin Nucl Med 1998, 28:352-358. 10.1016/S0001-2998(98)80038-X, 9800240.
10. Brucher BL, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001, 233:300-309. 10.1097/00000658-200103000-00002, 1421244, 11224616.
11. Flamen P, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002, 13:361-368. 10.1093/annonc/mdf081, 11996465.
12. Larson SM. Cancer or inflammation? a holy grail for nuclear medicine. J Nucl Med 1994, 35:1653-1655.
13. Song SY, et al. Fdg-pet in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 2005, 63:1053-1059. 10.1016/j.ijrobp.2005.03.033, 15964705.
14. Wieder HA, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004, 22:900-908. 10.1200/JCO.2004.07.122, 14990646.
15. Kong FM, et al. A pilot study of [18f]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol 2007, 25:3116-3123. 10.1200/JCO.2006.10.3747, 17634490.
16. Bakheet SM, et al. F-18 fdg uptake in benign esophageal disease. Clin Nucl Med 1999, 24:995-997. 10.1097/00003072-199912000-00026, 10595492.
17. Bhargava P, et al. Radiation-induced esophagitis on fdg pet imaging. Clin Nucl Med 2003, 28:849-850. 10.1097/01.rlu.0000090936.30974.e2, 14508282.
18. Brink I, et al. Effects of neoadjuvant radio-chemotherapy on 18f-fdg-pet in esophageal carcinoma. Eur J Surg Oncol 2004, 30:544-550. 10.1016/j.ejso.2004.03.007, 15135484.
19. Nijkamp J, et al. Relating acute esophagitis to radiotherapy dose using fdg-pet in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer. Radiother Oncol 2013, 106:118-123. 10.1016/j.radonc.2012.09.024, 23219463.